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ABSTRACT ARTICLE INFO
Human immunodeficiency virus (HIV)- infected patients are at risk of acquiring viral hepatitis, due to 
common routes of transmission. As the introduction of highly active antiretroviral therapy (HAART) 
reduced the frequency of opportunistic infections and improved survival, viral hepatitis emerged as 
an important cause of morbidity and mortality in HIV-infected cases. Occult hepatitis B virus (HBV) 
infection is characterized by presence of HBV infection without detectable hepatitis B surface antigen 
(HBsAg). There are conflicting reports on the impact of occult HBV infection on the natural history 
of HIV disease. In this review, we described the findings of studies on HIV and hepatitis B co-infection 
with focus on the prevalence of occult HBV infection. The results of this review demonstrated the 
importance of prevention, diagnosis and treatment of occult HBV infection in HIV-positive patients. 
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Background
Hepatitis B virus (HBV) infection is a serious global health 
problem, with two billion people infected worldwide and 360 
million suffering from chronic HBV infection (1). HBV infection 
is the tenth leading cause of death worldwide, accounting for 
520,000  to  1.2  million  deaths  each  year  (1-3).  The  prevalence 
of chronic HBV infection varies considerably in different geo-
graphical regions. China, sub-Saharan Africa and the Amazon 
Basin, have the highest prevalence with chronic carrier rates 
more  than  7%.  Japan,  the  Indian  subcontinent  and  southern 
parts of Eastern and Central Europe have intermediate preva-
lence with 2% to 7% of the population are chronic carriers of HBV. 
The Middle-East, Bahrain, Iran and Kuwait have low prevalence 
of chronic HBV infection (<2%) (2, 4-7). The prevalence of hepati-
tis B surface antigen (HBsAg) in Iran was reported to be between 
2.5% and 7.2% in 1979 (8). A more recent study showed that the 
prevalence of HBsAg is ranging from 1.7% to over 5% in different 
provinces  (9).  Occult  HBV  infection  (OBI)  is  characterized  by 
presence of HBV infection without detectable HBsAg. Most oc-
cult HBV carriers have very low viremia levels so the diagnosis of 
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OBI requires sensitive HBV-DNA PCR assay. A number of explana-
tions for the persistence of HBV-DNA in HBsAg-negative samples 
have  been  proposed,  including  integration  of  HBV-DNA  into 
host’s chromosomes, mutations in the major hydrophilic loop 
of the S gene, the window period following acute HBV infection, 
underlying HCV co-infection, immunosuppression, poor ability 
of laboratory in detection of HBsAg and the presence of immune 
complexes in which HBsAg may be hidden (10-13). The clinical 
implications of OBI involve different clinical aspects. OBI har-
bors potential risk for HBV transmission through hemodialysis, 
blood transfusion and organ transplantation. It can cause cryp-
togenic liver disease, acute exacerbation of chronic hepatitis B, 
or even fulminant hepatitis and development of hepatocellular 
carcinoma (10). Human immunodeficiency virus (HIV) causes a 
chronic and latent infection in the body which induces exten-
sive damage to the immune system. HIV-infected subjects show 
a quantitative depletion of CD4 cells and also an overall immune 
dysregulation (14). HBV is a frequent co-contaminant with HIV, 
because both share common modes of transmission (14) and it 
is an important cause of mortality and morbidity among HIV-in-
fected persons (15). In co-infected patients, the mortality rate is 
19 times higher than in HIV mono-infected individuals (16). The 
high rates of serological markers of HBV infection have been 
reported in HIV populations and can be as high as 68% (17-20). 
Isolated hepatitis B core antibodies (anti-HBc) are predominant 
serological pattern in these patients (17, 21) and can be associ-
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ated with OBI (19, 22). OBI in other high risk groups such as he-
modialysis patients was reviewed and published in Iran (23). In 
this review, we described the findings of studies on HIV and HBV 
co-infection with focus on the prevalence of OBI.
Hepatitis B Virus Infection in HIV-Infected Patients
HIV- infected patients are at risk of acquiring parenterally- or 
sexually-transmitted viruses including HBV. Approximately 20% 
of HIV-positive patients who acquire acute HBV infection devel-
op chronic HBV infection compared to only 5% of HIV-negative 
persons (15). Chronic HBV infection affects 7%-10% of HIV-infect-
ed  patients  with  large  differences  according  to  geographical 
region (7). After the introduction of highly active antiretroviral 
therapy (HAART) liver disease has emerged as a major cause of 
morbidity and mortality in HIV-infected subjects (24). In HIV-
HBV co-infected patients, it has been suggested that HIV inter-
feres with the natural history of HBV infection by enhancing 
HBV replication and higher HBV-DNA levels and decreased hepa-
titis B e-antigen (HBeAg) seroconversion, leading to more severe 
liver disease, more rapid progression of liver fibrosis and a high-
er rate of cirrhosis decompensation, end-stage liver disease and 
hepatocellular carcinoma (25, 26). There is controversial data on 
the activity of inflammatory liver disease in HBV-HIV co-infected 
patients. Some studies in Californian and French HIV-positive 
subjects  showed  increased  necro-inflammatory  activity  (27, 
28). In contrast, other studies from northern Europe and USA 
showed a significantly less severe necro-inflammatory activity 
in HIV-HBV co-infected men who have sex with men (MSM) (29, 
30). Besides, one study from the Central African Republic identi-
fied a lower prevalence of chronic hepatitis B in HIV-infected vs 
HIV-uninfected individuals (31). On the other hand, studies from 
the Cote d’Ivoire, Malawi, Thailand and Tanzania have reported 
similar chronic hepatitis B prevalence between HIV-uninfected 
and HIV-infected subjects (32-35).
OBI in HIV-Infected Patients
The prevalence of OBI in HIV-positive patients varies consider-
ably from 0% to 89.5% in different geographical regions (17-20, 
36). These discrepancies in the rate of OBI may reflect the diverse 
prevalence of HBV and HIV infections in different countries and 
the sensitivity of the assays used to detect the HBV-DNA. OBI is 
most frequently seen in patients with anti-HBc antibody as the 
only HBV serological marker. However, no anti-HBc or anti-HBs 
antibody could be detected in some individuals (37, 38). Nunez, et 
al, (18) did not detect HBV-DNA among 85 HIV-positive injection 
drug users and Bloquel, et al, (39) found OBI in 0.8% of French 
HIV-infected patients. In two studies from Brazil (40) and the 
Netherlands (41) the rate of OBI was reported to be 5% in HIV-in-
fected patients. In two other studies in South Africa, almost 22% 
of HIV-infected people without HBsAg had detectable HBV-DNA 
(36, 42). In another study, in two cohorts of HIV-positive patients 
in UK, approximately 14% of patients had OBI (43). Hofer, et al, 
(17) identified HBV-DNA in 89.5% of patients who had isolated an-
ti-HBc antibody. The other study by Firnhaber, et al, (44) showed 
that 88.4% of HIV-positive cases with isolated anti-HBc antibody 
had OBI. In another study in Iranian HIV-positive patients with 
isolated anti-HBc antibody, HBV-DNA was detected in 13.6% of the 
patients (25) compared to 24.5% of Indian and 28.7% of Lebanese 
HIV-infected patients with isolated anti-HBc (14, 45).
OBI in HIV-HCV Co-Infected Patients
Thirty-five million people have HIV infection worldwide, and 
approximately 20% of them had chronic hepatitis C (HCV) infec-
tion (46). HCV infection affects 25% of HIV-positive subjects, with 
greater rates (approximately 75%) in persons acquired infection 
through contaminated blood or blood products and intravenous 
drug users. Some studies have demonstrated that HIV infection 
modifies the natural history of HCV infections, increasing the 
progression to chronic disease and cirrhosis (25). With the ad-
vent of HAART, there has been a significant decrease in oppor-
tunistic infections, so HCV has emerged as an important cause 
of morbidity and mortality in HIV-infected patients. A study in 
French HIV-infected patients showed that deaths due to HCV-
related end-stage liver disease were more frequent in the HAART 
era than in the pre-HAART era (47). It was shown that HCV-HBV 
co-infection may result in a decrease in the replication of both 
viruses with greater effect on HBV. HCV core protein binds to 
HBV-DNA and suppresses HBV gene expression and replication 
(48). OBI may be encountered in HIV-HCV co-infected patients 
and may cause more severe liver disease and lower response 
to interferon therapy (49). Previous studies on the association 
between  HCV  infection  and  OBI  persistence  in  HIV-infected 
cases have given conflicting results (17, 18, 21). The percentage 
of OBI in HIV-HCV-positive patients varies considerably in dif-
ferent studies from less than 1% (50), to 1.4%–5% (51-53), 10% (54), 
33%–35% (20, 42) and more than 40% (55). In another study 21% of 
HIV-HCV co-infected patients had detectable HBV-DNA in their 
plasma and OBI was significantly higher in HCV co-infected sub-
jects than HCV-negative cases (56). Laguno, et al, found that OBI 
presents in at least 6.3% of HCV-HIV patients and in more than 
16% of cases with anti-HBc (57). Fabris, et al, showed that 13.4% of 
HCV-HIV co-infected patients had OBI (58). In another study in 
Iran HBV-DNA was detectable in 16.7% of HCV-HIV co-infected pa-
tients with isolated anti-HBc (59). Despite the reports regarding 
to strong association between HCV infection and OBI (58, 60-62), 
Jardim, et al, (40) reported no significant difference in the pres-
ence of HBV-DNA in HIV-positive patients with or without HCV 
infection. Daza, et al, (63) also found a very low rate of HBV-DNA 
in HIV-HCV co-infected patients. They reported that OBI is a rare 
finding in these patients.
Conclusions
Hepatic abnormalities are common in HIV-infected subjects. 
Due to shared routes of transmission, chronic HBV and HCV 
infections frequently complicate HIV disease. To date, there are 
controversial evidences regarding the influence of HBV infec-
tion on HIV disease progression. While some early studies sug-
gested that HBV-related liver disease may be less severe among 
HIV-infected patients, recent studies indicate an increased risk 
of  liver-related  morbidity  and  mortality  among  HIV-HBV  co-
infected patients. Current evidences demonstrated that OBI is 
relatively frequent in HIV-infected individuals. These data em-
phasize the importance of prevention, diagnosis and treatment 
of OBI in HIV-positive cases and all HIV-infected patients should 
be screened for evidence of resolved or active HBV infection. 
HCV infection is also common in HIV-infected individuals with 
parenteral exposure such as IDUs and recipients of blood prod-
ucts. Although the majority of HCV-HIV co-infected cases are as-
ymptomatic, HCV infection may lead to the development of he-
patic fibrosis, cirrhosis and hepatocellular carcinoma. There are 
conflicting reports on the impact of HCV infection on the natu-
ral history of HIV disease. With the advent of HAART, there has Occult HBV in HIV Ramezani A et al. 9
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